scholarly journals Anti-EJ, anti-MDA5 double-positive chronic clinically amyopathic dermatomyositis: a case report

2018 ◽  
Vol 2 (2) ◽  
Author(s):  
Yusuke Takeuchi ◽  
Motomu Hashimoto ◽  
Ran Nakashima ◽  
Masao Tanaka ◽  
Nobuo Kuramoto ◽  
...  
Keyword(s):  
Case Report ◽  
Amyopathic Dermatomyositis ◽  
Double Positive ◽  
Clinically Amyopathic Dermatomyositis

scholarly journals Clinically Amyopathic Dermatomyositis Caused by a Tattoo

2018 ◽  
Vol 2018 ◽  
pp. 1-4
Author(s):  
Bing Han ◽  
Qiang Guo
Keyword(s):  
Immune Response ◽  
Case Report ◽  
Interstitial Lung Disease ◽  
Laboratory Test ◽  
Clinical Presentation ◽  
Unknown Origin ◽  
Skin Lesions ◽  
Amyopathic Dermatomyositis ◽  
Clinically Amyopathic Dermatomyositis ◽  
Left Chest

Introduction. Clinically amyopathic dermatomyositis (CADM) is a rare disease with unknown origin. It is characterized by the specific skin lesions of dermatomyositis (DM) without clinical or laboratory evidence of myopathy. Previous studies indicated that tattoo may induce immune response. Case Report. A 22-year-old male who tattooed butterfly on the left chest with blue and red ink. Then, he gradually had typical Gottron rash and interstitial lung disease (ILD) without weakness of the muscle. The clinical presentation and laboratory test represent the diagnosis of CADM. According to the history, CADM was induced by the tattoo five months before admission. Discussion. We first reported the CADM induced by a tattoo. However, further studies are still needed to approach the specific substances within the tattoo that trigger immune response.

scholarly journals Clinically Amyopathic Dermatomyositis Associated with Recurrence of Esophageal Cancer: A Case Report

2021 ◽  
Vol 5 (3) ◽  
pp. 297-300
Author(s):  
Anna Eversman ◽  
Sayeeda Ahsanuddin ◽  
Joel Saltzman ◽  
Paula Silverman ◽  
Mara Beveridge
Keyword(s):  
Esophageal Cancer ◽  
Case Report ◽  
Esophageal Adenocarcinoma ◽  
Clinical Significance ◽  
Amyopathic Dermatomyositis ◽  
Case Presentation ◽  
Skin Changes ◽  
Clinically Amyopathic Dermatomyositis ◽  
Clinical Interest ◽  
New Onset

Background: Approximately 20% of patients displaying skin changes characteristic of dermatomyositis do not develop clinical or enzymatic evidence of muscle inflammation within 6 months of onset, leading to a diagnosis of clinically amyopathic dermatomyositis (CADM). While the association between dermatomyositis and malignancy is well-documented, the clinical significance of CADM is still being elucidated. Case Presentation: We report a case of new-onset CADM associated with recurrent esophageal adenocarcinoma for clinical interest and to add to the limited literature on CADM. Conclusion: To date, there is only one report of concurrent CADM and esophageal cancer. We present this case for clinical interest and to add to the limited literature on CADM.

scholarly journals Case Report: Rapidly Progressive Interstitial Lung Disease in A Pregnant Patient With Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis

2021 ◽  
Vol 12 ◽  
Author(s):  
Cuihong Chen ◽  
Yulan Chen ◽  
Qin Huang ◽  
Qiu Hu ◽  
Xiaoping Hong
Keyword(s):  
Case Report ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Pregnant Patient ◽  
Amyopathic Dermatomyositis ◽  
Clinically Amyopathic Dermatomyositis ◽  
First Case ◽  
Immunosuppressant Regimen ◽  
Present Case Study

Dermatomyositis occurs extremely rarely during pregnancy. A number of studies in the published literature have documented how the outcome of pregnancy is poor for both mother and fetus. The present case study reports on a patient who was diagnosed with clinically amyopathic dermatomyositis complicated by interstitial lung disease during pregnancy, and was successfully treated with a combined immunosuppressant regimen. To the best of the authors’ knowledge, this is the first case study detailing how a pregnant woman with clinically amyopathic dermatomyositis with positive anti-melanoma differentiation-associated gene 5 antibody achieved complete remission after early intervention of combined immunosuppressive therapy without residual pulmonary interstitial changes.

Sign in / Sign up

Export Citation Format

Share Document